Clinical trial
Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD
NCT00291408 · Imperial College London, Other · Withdrawn
Key facts
| NCT number | NCT00291408 |
|---|---|
| Title | Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD |
| Official title | A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Symbicort® and Pulmicort® on HAT and HDAC Expression and Activity in Induced Sputum Cells Obtained From COPD Patients. |
| Lead sponsor | Imperial College London, Other |
| Collaborators | AstraZeneca Industry |
| Status | Withdrawn |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD), Age Matched Healthy Volunteers (Non-smokers) |
| Intervention type | Procedure |
| Interventions | Skin Prick Test, Impulse Oscillometry, Exhaled Nitric Oxide, Spirometry, Reversibility, Exhaled Breath Condensate, Sputum Induction |
| Enrollment | 0 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Feb 14, 2006 |
| Last update posted | Aug 7, 2019 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: